DNA clues could predict which prostate cancer patients benefit from Bone-Targeting drug
NCT ID NCT04489719
Summary
This study aims to understand why some men with advanced prostate cancer that has spread to bones respond better to the drug radium-223 than others. Researchers will test blood samples from 48 patients to look for specific DNA repair defects that might make the cancer more sensitive to this treatment. The goal is to help doctors better predict which patients are most likely to benefit from this FDA-approved therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bozeman Health Deaconess Hospital
ACTIVE_NOT_RECRUITINGBozeman, Montana, 59715, United States
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21287, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Wisconsin-Madison
RECRUITINGMadison, Wisconsin, 53705, United States
Contact
Conditions
Explore the condition pages connected to this study.